<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173770</url>
  </required_header>
  <id_info>
    <org_study_id>ADC3680-01</org_study_id>
    <nct_id>NCT01173770</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ADC3680B in Healthy Volunteers</brief_title>
  <official_title>A Double-Blind Randomized, Placebo-Controlled, Dose Escalating Study to Assess The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ADC3680B Administered Orally to Healthy Volunteers and to Investigate Food Effects on Pharmacokinetics After Single Oral Doses of ADC3680B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmagen Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmagen Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a First-In-Man study designed to examine the safety, tolerability, pharmacokinetics
      and functional activity of ADC3680B after single and multiple doses in healthy male
      volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single doses of ADC3680B determined by adverse event reporting, clinical laboratory tests, vital signs and ECGs</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of multiple doses of ADC3680B determined by adverse event reporting, clinical laboratory tests, vital signs and ECGs</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose pharmacokinetics of ADC3680B</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple dose pharmacokinetic of ADC3680B</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ADC3680B under fasted and fed conditions</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil shape change in response to stimulation with PGD2 in whole blood ex vivo</measure>
    <time_frame>Pre-dose and up to 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1: ADC3680B vs. Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: ADC3680B vs. Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: ADC3680B vs Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: ADC3680B vs. Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: ADC3680B vs. Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: ADC3680B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADC3680B</intervention_name>
    <description>Escalating single doses ADC3680B or Placebo over 5 study periods</description>
    <arm_group_label>Cohort 1: ADC3680B vs. Placebo</arm_group_label>
    <arm_group_label>Cohort 2: ADC3680B vs. Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADC3680B</intervention_name>
    <description>ADC3680B or Placebo for 7 days</description>
    <arm_group_label>Cohort 3: ADC3680B vs Placebo</arm_group_label>
    <arm_group_label>Cohort 4: ADC3680B vs. Placebo</arm_group_label>
    <arm_group_label>Cohort 5: ADC3680B vs. Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADC3680B</intervention_name>
    <description>Single doses ADC3680B over 2 study periods under fasted and fed conditions</description>
    <arm_group_label>Cohort 6: ADC3680B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years

          -  Body Mass Index (BMI) of 18 to 30 kg/m2

          -  Signed and dated written informed consent prior to admission into the study

          -  Willing and able to comply with the requirements of the protocol and available to
             complete the study

        Exclusion Criteria:

          -  Evidence of history of any clinically significant medical disorder

          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Febbraro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec</name>
      <address>
        <city>Merthyr Tydfil</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2010</study_first_posted>
  <last_update_submitted>February 1, 2011</last_update_submitted>
  <last_update_submitted_qc>February 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Salvatore Febbraro</name_title>
    <organization>Simbec Research Limited</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

